Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$9.05 USD

9.05
952,062

+0.14 (1.57%)

Updated Aug 29, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug

The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.

Tirthankar Chakraborty headshot

This September Could Be Different: 5 Stocks to Buy

In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.

Sreoshi Bera headshot

Major Indexes Erase Pandemic-Led Losses: 5 Top Picks

Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most

Emergent Biosolutions (EBS) Up 21.2% Since Last Earnings Report: Can It Continue?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo

Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.

Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes

Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.

Alnylam's Share Price Rises YTD on Pipeline Developments

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

Here's Why Hold Strategy is Apt for Acadia Healthcare Stock

Acadia Healthcare (ACHC) continues to benefit from increasing demand for telehealth services, strategic buyouts and solid financial position.

Amarin (AMRN) in Focus: Stock Moves 5.5% Higher

Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio

ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.

Centene's Contract Renewal to Aid Medicaid Members in Indiana

Centene's (CNC) subsidiary MHS gets a contract renewal through which it will be able to efficiently serve its Medicaid members in Indiana.

Encompass Health Forms JV to Efficiently Serve South Carolina

Encompass Health (EHC) and MUSC Health intend to offer improved healthcare services in South Carolina through a joint venture.

Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study

Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.

Emergent BioSolutions' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.

The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics

The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics

Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag

The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.

Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline

Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.

Unity Biotechnology (UBX) Jumps: Stock Rises 7.1%

Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher

Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Looking for a Growth Stock? 3 Reasons Why Emergent Biosolutions (EBS) is a Solid Choice

Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.

Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod

Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.

5 Biotech Stocks Up More Than 100% This Year So Far

Here we discuss five biotech companies recording impressive growth so far in 2020.

5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus

Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.

Axsome's NDA Filing for Migraine Candidate in Q4 on Track

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.

Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline

Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.